NCT06680466View on ClinicalTrials.gov

A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

July 15, 2024

Study Completion Date

November 30, 2024

Conditions

Pain

Interventions

DRUG

YZJ-4729

Dose Group 1

DRUG

morphine

morphine,

DRUG

placebo

DRUG

YZJ-4729

Dose Group 2

DRUG

YZJ-4729

Dose Group 3

DRUG

YZJ-4729

Dose Group 4

Trial Locations (1)

Unknown

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06680466 - A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery | Biotech Hunter | Biotech Hunter